精品久久久久中文慕人妻,男女做暧暧禁止18免费,91天堂亚洲无码艹逼,乱伦3PaV片
About Us
Company Introduction
Strategic Development
Social Responsibility
Scientific Research
Innovative Layout
Innovative Field
International
Global Expansion
Cooperative Partner
Global R&D Centers
International Cooperation
Investor Relations
Information Disclosure
Corporate Governance
Stock Information
ESG
Contact us
Products Services
Product center
Product branding
Quality & Safety
News
Company News
Media Coverage
Media Inquiries
Multimedia zone
Career
Talent
R&D Team
Employee Life
Job Opportunities
EN
CN
About Us
· Company Introduction
· Strategic Development
· Social Responsibility
Scientific Research
· Innovative Layout
· Innovative Field
Products Services
· Product center
· Product branding
· Quality & Safety
News
· Company News
· Media Coverage
· Media Inquiries
· Multimedia zone
Vocational
· Concept about Talent
· R&D Team
· Employee Life
· Job Opportunities
NEWS CENTER
>
News
>
Company
Company News
Media Coverage
Media Inquiries
Media Center
2020-11-25
NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA
2020-11-13
First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141
2020-11-09
Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment
2020-11-01
GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation in Anti-tumor Field
2020-08-11
GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily
2020-07-28
GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy
2020-07-28
GP (HK) Enters into a Capital Subscription and Acquisition Agreement, Acquires the Third-Generation Stent Retriever Contributing to Achieve the Strategic Plan of “Treating the Heart and Brain with the Same Therapeutic Method”
2020-06-01
GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas
2020-05-19
GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company
2020-05-08
GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control
2020-04-28
GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market
2020-04-14
Grandpharma Introduces the Global Innovative Drug CBT001 in Ophthalmology Field
Page 7 of 8
?
?
...
4
5
6
7
8
?
About Us
Company Introduction
Strategic Development
Social Responsibility
Scientific Research
Innovative Layout
Innovative Field
International
Global expansion
Cooperative Partner
Global R&D Centers
International Cooperation
Investor Relations
Information Disclosure
Corporate Governance
Stock Information
Contact us
Products Services
Product Center
Product branding
Quality & Safety
News
Company News
Media Coverage
Media Inquiries
Multimedia zone
Vocational
Concept about Talent
R&D Team
Employee Life
Job Opportunities
Copyright ? Grand Pharma (China) Co., Ltd. All Rights Reserved
E ICP B 10008288
EGWAB 42010402000597
Legal Provisions